Showing all 3 results
Entacavir Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended, High-Density Microdose Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips or heavy-gauge HDPE bottles to ensure the absolute chemical stability of the potent antiviral API.
Active Ingredient Strength Primary Clinical Function Entecavir (as Monohydrate) USP/Ph.Eur. 0.5 mg The Global Nucleoside-Naive Standard: The definitive ultra-micro-dose utilized for the daily, lifelong suppression of HBV in patients who have never received prior antiviral therapy. Entecavir (as Monohydrate) USP/Ph.Eur. 1.0 mg The Refractory & Cirrhosis Standard: Double-strength therapeutic payload utilized specifically for patients with Lamivudine-resistant HBV viremia or those suffering from decompensated liver cirrhosis. Excipients Lactose Monohydrate / Microcrystalline Cellulose / Crospovidone / Magnesium Stearate / Premium Polymeric Film Diluent / Binder / Superdisintegrant / Lubricant / Film-Coating (Engineered specifically utilizing advanced multi-stage geometric dilution to ensure the microscopic 0.5mg payload is flawlessly distributed throughout the tablet matrix, preventing toxic “hot spots” or sub-therapeutic failures) *Pack Sizes: 3×10 Alu-Alu Blisters or Bottles of 30 (Optimized specifically for strict 30-day chronic hepatology dispensing regimens).
Erlotinib Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended, High-Density Film-Coated Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips or heavy-gauge HDPE bottles to ensure the absolute chemical stability of the targeted antineoplastic API.
Active Ingredient Strength Primary Clinical Function Erlotinib (as Hydrochloride) USP/Ph.Eur. 100 mg The Pancreatic Oncology Standard: The definitive daily maintenance dose utilized globally in combination with Gemcitabine for advanced, unresectable, or metastatic pancreatic cancer. Erlotinib (as Hydrochloride) USP/Ph.Eur. 150 mg The Thoracic Oncology Standard: Massive therapeutic payload utilized as a first-line, maintenance, or second-line daily monotherapy for EGFR-mutated Non-Small Cell Lung Cancer. Excipients Lactose Monohydrate / Microcrystalline Cellulose / Sodium Starch Glycolate / Sodium Lauryl Sulfate / Magnesium Stearate / Premium Polymeric Film Diluent / Binder / Superdisintegrant / Surfactant / Heavy Film-Coating (Engineered specifically to maximize dissolution of this highly insoluble compound while locking the potent cytotoxic API safely inside the tablet, completely preventing handler exposure to carcinogenic dust) *Pack Sizes: 3×10 Alu-Alu Blisters or Bottles of 30 (Optimized specifically for strict 30-day chronic oncology dispensing regimens).
Fluconazole & Ivermectin Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended, High-Density Microdose FDC Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips to ensure the absolute chemical stability of both active pharmaceutical ingredients.
Active Ingredient Strength Primary Clinical Function Fluconazole USP/Ph.Eur. 150 mg The Antifungal Anchor (Macro-Dose): The foundational triazole payload required to systematically eradicate widespread dermatophytes and yeasts. Ivermectin EP/USP 6 mg / 12 mg The Antiparasitic Assassin (Micro-Dose): The highly potent, targeted neurotoxin required to paralyze burrowing mites, lice, and severe helminthic infections. Excipients Microcrystalline Cellulose / Croscarmellose Sodium / Povidone K-30 / Colloidal Silicon Dioxide / Magnesium Stearate / Premium Polymeric Film Diluent / Superdisintegrant / High-Shear Binder / Glidant / Film-Coating (Engineered specifically utilizing advanced multi-stage geometric dilution to ensure the lethal 6mg micro-dose of Ivermectin is flawlessly distributed throughout the massive Fluconazole matrix, preventing toxic “hot spots”) *Pack Sizes: Single-Dose Blister Packs (1×1 or 1×2) or 10×10 Blisters (Optimized specifically for rapid NGO deployment and “stat” dosing protocols).
